EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis

Javier Munoz, Allison Rosenthal, Andrew Ip, Justin M Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Tychell Branchcomb, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum und 8 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2025.10.010 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Javier Munoz und 19 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, Phoenix, AZ. Electronic address: munoz.javier@mayo.edu. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Rituximab, Antineoplastic Combined Chemotherapy Protocols, Oxaliplatin. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This indirect treatment comparison evaluated epcoritamab plus gemcitabine and oxaliplatin (Epcor+GemOx) versus rituximab (R)-GemOx in patients with transplant-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). METHODS: Individual patient data (IPD) for Epcor+GemOx from EPCORE NHL-2 Arm 5 (NCT04663347) were compared with clinical practice data for patients treated with R-GemOx using 2 methodologies: a matching-adjusted indirect comparison (MAIC) using published aggregate data from clinical sites in France (Cazelles et al. Lymphoma. 2021;62:2161) and inverse probability of treatment weighting (IPTW) using IPD from the US-based COTA database (COTA Healthcare). Outcomes included objective response rate (ORR), complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). RESULTS: In the MAIC, after adjustment, Epcor+GemOx versus R-GemOx had significantly higher ORR (86.8% vs 38.3%; relative risk [RR], 2.27 [95% confidence interval (CI), 1.76-2.93]; P < .0001) and CR rate (71.2% vs 32.7%; RR, 2.18 [95% CI, 1.61-2.96]; P < .0001). Median PFS was 26.7 versus 4.8 months (hazard ratio [HR], 0.38 [95% CI, 0.22-0.67]; P < .001); median OS was not reached with Epcor+GemOx versus 10.0 months with R-GemOx (HR, 0.54 [95% CI, 0.29-1.00]; P = .05). In the IPTW, Epcor+GemOx versus R-GemOx had significantly higher ORR (88.5% vs 35.6%; RR, 2.48 [95% CI, 1.80-3.43]; P < .0001), CR rate (63.9% vs 10.2%; RR, 6.25 [95% CI, 3.08-12.68]; P < .0001), median PFS (11.2 vs 2.4 months; HR, 0.23 [95% CI, 0.15-0.36]; P < .001), and median OS (21.6 vs 8.3 months; HR, 0.47 [95% CI, 0.30-0.74]; P = .002). CONCLUSION: Epcor+GemOx provides significantly greater response rates and survival outcomes compared with R-GemOx in patients with transplant-ineligible R/R DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseRituximabAntineoplastic Combined Chemotherapy ProtocolsOxaliplatinDeoxycytidineHumansMaleGemcitabineFemaleAgedMiddle AgedAdultAged, 80 and overNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Bispecific antibodyIndirect treatment comparisonNon-Hodgkin lymphomaOverall survivalResponse rate

Substanzen

RituximabOxaliplatinGemcitabineDeoxycytidine

Autor:innen und Institutionen

  • Mayo Clinic, Phoenix, AZ. Electronic address: munoz.javier@mayo.edu.
  • Mayo Clinic, Phoenix, AZ.
  • Hackensack Meridian School of Medicine, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.
  • Cedars-Sinai Medical Center, Los Angeles, CA.
  • Genmab US Inc., Plainsboro, NJ.
  • Genmab, Copenhagen, Denmark.

Förderung

  • AbbVie Inc

Zitieren

APA

Munoz, J., Rosenthal, A., Ip, A., Darrah, J. M., Wang, T., Zhang, G., Mutebi, A., Branchcomb, T., Ding, Z., Chhibber, A., Navarro, F. R., Risum, M., Atiya, M., Brodkin, S., Wang, A., Alshreef, A., Harb, D., Sacchi, M., Hoehn, D., & Karimi, Y. H. (2026). Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.010

Vancouver

Munoz J, Rosenthal A, Ip A, Darrah JM, Wang T, Zhang G, et al. Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.10.010

BibTeX
@article{Munoz2026,
  author = {Munoz, Javier and Rosenthal, Allison and Ip, Andrew and Darrah, Justin M and Wang, Tongsheng and Zhang, Guihua and Mutebi, Alex and Branchcomb, Tychell and Ding, Zhijie and Chhibber, Anindit and Navarro, Fernando Rivas and Risum, Malene and Atiya, Mohammad and Brodkin, Samantha and Wang, Anthony and Alshreef, Abualbishr and Harb, Diala and Sacchi, Mariana and Hoehn, Daniela and Karimi, Yasmin H},
  title = {Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2025.10.010}
}
Kostenlos starten →